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DAMs are membrane-anchored proteases that regu-
late cell behavior by proteolytically modifying the
cell surface and ECM. Like other membrane-anchored
proteases, ADAMs contain candidate “adhesive” domains
downstream of their metalloprotease domains. The mecha-
nism by which membrane-anchored cell surface proteases
utilize these putative adhesive domains to regulate protease
function in vivo is not well understood. We address this
important question by analyzing the relative contributions
of downstream extracellular domains (disintegrin, cysteine
rich, and EGF-like repeat) of the ADAM13 metalloprotease
during 
 
Xenopus laevis
 
 development. When expressed in
embryos, ADAM13 induces hyperplasia of the cement
gland, whereas ADAM10 does not. Using chimeric con-
A
 
structs, we ﬁnd that the metalloprotease domain of
ADAM10 can substitute for that of ADAM13, but that
speciﬁcity for cement gland expansion requires a downstream
extracellular domain of ADAM13. Analysis of ﬁner resolution
chimeras indicates an essential role for the cysteine-rich
domain and a supporting role for the disintegrin domain.
These and other results reveal that the cysteine-rich do-
main of ADAM13 cooperates intramolecularly with the
ADAM13 metalloprotease domain to regulate its function
in vivo. Our ﬁndings thus provide the ﬁrst evidence that a
downstream extracellular adhesive domain plays an active
role in regulating ADAM protease function in vivo. These
ﬁndings are likely relevant to other membrane-anchored
cell surface proteases.
 
Introduction
 
Proteolysis at the cell surface is a critical mediator of develop-
mental processes, cellular homeostasis, and tissue repair, but
can play deleterious roles in disease states. By cleaving ECM
components and cell adhesion receptors, cell surface proteolysis
can have profound effects on cell–matrix and cell–cell inter-
actions. Proteolysis at the cell surface also accounts for
ectodomain shedding, the process of cleaving latent progrowth
factors and cytokines to release active forms from cell
membrane attachments.
Four classes of membrane-anchored cell surface proteases
have been identified that participate in these cleavage events:
membrane-type matrix metalloproteases (MT-MMPs),*
ectopeptidases,  meprins, and ADAMs (a disintegrin and
metalloprotease) (Stocker and Bode, 1995; Bauvois, 2001).
Most of these cell surface proteases are type I integral mem-
brane proteins that contain additional domains downstream of
their protease domains (Fig. 1). Some of these nonproteolytic
ectodomain elements have been shown to serve adhesive
functions in vitro (Overall, 2002). For example, the hemopexin
domain of MT1-MMP, the cysteine-rich domain of dipepti-
dylpeptidase IV, and the disintegrin and/or cysteine-rich
domain of 
 
Xenopus
 
 ADAM13 have been shown, in in vitro
biochemical experiments, to interact with ECM components
such as collagen and fibronectin (De Meester et al., 1999;
Seiki, 1999; Gaultier et al., 2002). The disintegrin domains
of several ADAMs have also been shown to support integrin-
mediated cell adhesion (Takahashi et al., 2001; Bridges et al.,
2002; Eto et al., 2002). Very little is known about the role of
the cysteine-rich domain in overall ADAM function. One
recent in vitro study reported that the cysteine-rich domain
of ADAM12 can interact with syndecans and mediate integrin-
dependent cell spreading (Iba et al., 2000). Although various
in vitro binding partners for these putative adhesive domains
have been identified, it is not known if, or how, this binding
might contribute to substrate selection and proteolytic function
in vivo. We are investigating these fundamental questions for
ADAM proteases.
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ADAM metalloproteases have been implicated in diverse
developmental events such as fertilization, ECM remodel-
ing, growth factor ectodomain shedding, and neurogenesis.
ADAM proteases have a wide variety of substrates. They can
degrade ECM components, shed cell-bound ectodomains to
free growth factors and ligands from the cell surface, and
cleave other integral membrane proteins (Blobel, 2000; Pri-
makoff and Myles, 2000; Moss et al., 2001; Kheradmand
and Werb, 2002). Through these mechanisms, ADAMs par-
ticipate in cell migration, morphogenesis, tissue repair, and
cell fate decisions. For the present study, we constructed chi-
meras between 
 
Xenopus
 
 ADAM10 and -13 in order to assess
the contributions of the downstream, nonproteolytic do-
mains to overall ADAM protease function in vivo. Although
similarly structured, ADAMs 10 and 13 have different roles
in development.
 
Xenopus
 
 ADAM13 is required for cranial neural crest cell
migration, possibly by remodeling the fibronectin matrix en
route (Alfandari et al., 2001). In addition to causing alter-
ations in cranial neural crest morphology and behavior,
overexpression of transcripts encoding ADAM13 results in
hyperplasia of the cement gland (Cousin et al., 2000). The
cement gland is the first ectodermally derived organ to dif-
ferentiate in 
 
Xenopus
 
 embryos. It arises in the anteriormost
part of the embryo and marks the dorsal–ventral axis bound-
ary. Cement gland induction requires a gradient of the
growth factor bone morphogenetic protein-4 (BMP4) as
well as counter expression of its inhibitors such as noggin,
 
follistatin, and chordin. Retinoic acid, eFGF, and Xwnt8 are
also required to make a cement gland (Sive and Bradley,
1996). Many of these growth factors are first synthesized as
membrane-tethered precursors and require extracellular pro-
teolysis (shedding) to become active.
The 
 
Drosophila
 
 ADAM kuzbanian (kuz, also ADAM10)
participates in axon extension through the ECM; kuz-null
axons fail to form outgrowths (Fambrough et al., 1996;
Schimmelpfeng et al., 2001). This failure of extension could
be due to the matrix-degrading actions of kuz, or to its abil-
ity to bind and cleave ephrins (Ilan and Madri, 1999). Loss
of kuz function in fly embryos results in perturbation of
Notch signaling, which affects neurogenesis (Pan and Ru-
bin, 1997; Lieber et al., 2002). Preliminary work in 
 
Xenopus
 
suggests that ADAM10 plays a role in frog primary neuro-
genesis as well (Pan and Rubin, 1997). X-ADAM10 mRNA
is expressed maternally throughout the embryo and then
later becomes restricted to a pan-neural expression pattern
(Pan and Rubin, 1997). As shown here, ADAM10 tran-
scripts are also detected in the developing cement gland be-
fore its maturation. Although overexpression of wild-type
ADAM10 message alters neural development, it has no af-
fect on the genesis of the cement gland.
From our analyses of chimeras encoding domains of
ADAMs 10 and 13, we find that the metalloprotease domain
of either ADAM13 or ADAM10 is capable of inducing ce-
ment gland hyperplasia, but only if attached to the down-
stream adhesive domains of ADAM13. Further analyses
indicate that the cysteine-rich domain of ADAM13 is abso-
lutely essential to induce ectopic, expanded cement glands
and, moreover, a disintegrin domain is required to support
this behavior. Our data indicate that the cysteine-rich do-
mains of ADAMs are important players in the biology of
ADAM proteases in vivo. By extension, the nonproteolytic
extracellular adhesive domains of other cell surface pro-
teases (MT-MMPs, ectopeptidases, and meprins) may play
similar roles.
 
Results
 
X-ADAM10 contains an extended HEXGH box sequence 
found in active metalloproteases
 
Xenopus
 
 ADAM10 was cloned by homology PCR using de-
generate primers based on the sequence of 
 
Drosophila
 
 kuz
and bovine ADAM10. A 1-kbp product was amplified from
stage-34 
 
Xenopus
 
 cDNA. Once the identity was confirmed
by sequence analysis, a 
 
Xenopus
 
 stage-45 cDNA library was
screened using the PCR fragment. Two X-ADAM10 clones
of 2.5 kbp and 3 kbp were isolated. Each clone contained 3
 
 
 
UTRs, but lacked the 5
 
 
 
 end. A 
 
Xenopus
 
 stage-17 cDNA li-
brary was screened using the larger clone in order to obtain
a full-length cDNA. This screen yielded eight additional
X-ADAM10 cDNAs, several of which contained the entire
ADAM10 coding sequence. The full-length cDNA clone
(GenBank/EMBL/DDBJ accession no. AF508151) has
high sequence similarities with other ADAM10 family
members: 80% identity with both bovine and human
ADAM10 and 27% identity with 
 
Drosophila
 
 kuz. The
 
Drosophila
 
 genome contains two 
 
kuz/ADAM10
 
 genes
Figure 1. Schematic representation of cell surface proteases. Each 
is anchored in the membrane with a transmembrane domain or GPI 
linker. MT-MMPs and ectopeptidases come in both types, whereas 
meprins and ADAMs both possess transmembrane domains and 
cytoplasmic tails of varying sizes. Some ADAMs have SH3 ligand 
domains within their cytoplasmic tails. The cytoplasmic tails of 
meprin   subunits have a PKC phosphorylation site. 
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(GenBank/EMBL/DDBJ accession nos. AE003640 and
AAF56926), which share high protein sequence similarities
with X-ADAM10. Over the entire coding region 
 
Xenopus
 
ADAM10 and -13 share 20% identity, although the metal-
loprotease domains alone are more similar (23% identity)
than the disintegrin domains (18% identity) when com-
pared separately (Fig. 2). The sequence of X-ADAM10
contains a predicted metalloprotease extended active site.
ADAM10 also has one putative SH3 binding domain (NP-
KLPPPKPL) within its cytoplasmic tail (Fig. 2). A partial
cDNA clone containing part of the disintegrin and cys-
teine-rich domains of 
 
Xenopus
 
 ADAM10 was reported pre-
viously (Pan and Rubin, 1997) and is 97% identical to the
corresponding portion of the deduced full-length protein
sequence reported here. This suggests that these two cDNAs
represent distinct ADAM10 pseudoalleles, which are com-
monly obtained from libraries prepared from tetraploid spe-
cies such as 
 
X
 
.
 
 laevis
 
.
 
Overexpression of ADAM13, but not ADAM10, 
causes hyperplasia of the cement gland
 
ADAM13 mRNA expression directly abuts the cement gland
primordium dorsally before its specification (Fig. 3) and,
when misexpressed anteriorly, enlarges the field of cells that
become cement gland (Cousin et al., 2000; Fig. 4 D). To in-
vestigate the role of ADAM13 in cement gland organogene-
sis, transcripts encoding wild-type ADAM13 were microin-
jected into one cell of a two-cell embryo (Fig. 4 A). The
embryos were then allowed to recover and grow under obser-
vation. When ADAM13 transcripts are misexpressed anteri-
orly by injection into the animal pole region of the embryo,
33% of the embryos have dorsally expanded cement glands
(Fig. 4 D). This hyperplasia is not seen when transcripts en-
coding ADAM13, with a point mutation in the catalytic ac-
Figure 2. Sequence comparison of X-ADAM10 and X-ADAM13. 
Amino acid sequence alignments of full-length ADAM10 (GenBank/
EMBL/DDBJ accession no. AF508151) and ADAM13 (accession no. 
U66003) with domain boundaries in black. The putative signal 
sequences are shown with an arrowhead. The cysteine-switch 
cysteine is indicated by a star ( ) and all potential N-linked 
glycosylation sites in ADAM10 are denoted with an open arrow (⇓). 
The metalloprotease active site is underlined by a solid black 
line, the disintegrin loop is underlined by a broken line, and the 
transmembrane (TM) domain is underlined with a wavy line. All 
putative SH3 binding sites in the cytoplasmic tails of ADAMs 10 
and 13 are boxed. Mutated amino acids in the zinc binding site 
(ADAM13 E341 to A; ADAM10 E385 to A) and the disintegrin loop 
(ADAM10 S529 to A and D530 to A; ADAM13 G474 to A, S475 to 
A, and D477 to A) are highlighted in bold.
Figure 3. Localization of ADAM13, ADAM10, and XCG mRNA in 
early Xenopus embryos. (A) In an anterior view at stage 16, ADAM13 
(purple, black arrow) mRNA is found in the neural crest and just 
dorsal to the cement gland anlagen (as marked by XCG mRNA 
expression in red, arrowhead), but the two transcripts do not 
overlap. (B) ADAM10 (light purple, open arrow) mRNA is localized 
to the entire neural plate and placodes, and encompasses the 
expression field of XCG. No distinct red color revealing XCG mRNA 
expression is seen because it is overlaid by the light purple ADAM10 
costaining. (C) In a schematic of the Xenopus embryo at stage 16, 
the pink represents the entire neural plate and surrounding placodal 
and cement gland anlagen that express ADAM10 mRNA (open arrow). 
The ADAM10-expressing area encompasses both the regions of 
ADAM13 mRNA expression (blue, black arrow) and XCG (red, 
arrowhead) (Nieuwkoop and Faber, 1994). 
896 The Journal of Cell Biology 
 
|
 
 
 
Volume 159, Number 5, 2002
 
tive site, is injected (Fig. 4 E, E/A ADAM13). When the
same animal pole injections were performed using transcripts
for wild-type ADAM10 (Fig. 4 F), no alterations in the ce-
ment gland were observed. Alterations in the expression of
the cement gland marker XCG were detected by XCG in situ
hybridizations and quantified by RNA spot blot. By stage
17, embryos injected with ADAM13 mRNA express more
XCG RNA than either noninjected embryos or embryos in-
jected with ADAM10 or E/A ADAM13 (Fig. 4 B).
 
ADAM10/13 chimeras are processed and transported 
to the cell surface
 
Because overexpression of ADAM13, but not ADAM10,
leads to enlargement of the cement gland, we were able to
undertake a study of how specific domains of ADAM13 are
involved in specifying this activity. To do this, we switched
domains between ADAM10 and -13 individually or as
units. The pro and metalloprotease domains (Pro/Met, PM)
were substituted as a unit and contained either the wild-type
sequence or an E to A mutation (denoted by an X) in the
protease active site (Fig. 5). Point mutations were also made
in the disintegrin loops of ADAMs 10 and 13 in order to in-
vestigate disintegrin domain contributions to overall ADAM
function. The resulting constructs (Fig. 5) were injected into
embryos and assayed for expression and prodomain removal.
The constructs were organized into four sets (Fig. 5 and see
Fig. 7, Sets A–D) to simplify discussion throughout the text.
Set A was developed to test whether ADAM 13 protease ac-
tivity is required for cement gland hyperplasia. Set B con-
structs were designed to investigate whether specificity of
protease activity resides within the protease domain or,
rather, within one or more downstream domains. Set C was
used to evaluate the critical role of the cysteine-rich domain
in specifying protease activity. Set D constructs established
the role of the ADAM13 disintegrin loop in supporting bio-
logical activity. All chimeras were processed to a putative
metalloprotease active form (met form) of the approximate
expected size based on calculated molecular weights (Fig. 6
A–C, open arrows).
Western blots of whole embryo lysates injected with
ADAM transcripts revealed that wild-type ADAM13 was
present at lower levels compared with ADAM10, whereas all
pro/met domain chimeras and E/A ADAM13 were present at
levels comparable to ADAM10 (Fig. 6 A). All disintegrin and
cysteine-rich (DC) domain chimeras (with or without the
Figure 4. Overexpression of wild-type ADAM13, but not ADAM10, 
results in hyperplasia of the cement gland. (A) Transcripts encoding 
ADAM constructs are microinjected into the animal pole of one 
blastomere at the two-cell stage. The embryos are allowed to 
recover until stage 22
 , and then fixed for whole mount in situ 
hybridization with the cement gland marker XCG. (B) The increase 
in XCG mRNA levels caused by ADAM13 overexpression was 
quantified by RNA spot blot. Data are represented as relative values 
of expression based on average pixel densities obtained using the 
PhosphorImager. All levels of expression were within the linear 
range of this detection method. Data are shown as means   SD of 
five independent experiments, each with pooled RNAs from 10 
embryos. By stage 17, a twofold increase in XCG mRNA levels 
(P   0.05) was found in embryos expressing ADAM13, but not E/A 
ADAM13 or ADAM10. The differences in XCG mRNA levels 
quantified by RNA spot blot were also observed by whole mount in 
situ hybridization. (C) GFP-injected embryos had no alterations 
in the cement gland marker XCG (black arrow), whereas large, 
ectopic islands of XCG-positive cells (D, arrow) were found when 
overexpressing ADAM13. Expression of the E/A ADAM13 mutant (E) 
or ADAM10 (F) had no affect on cement gland formation. NI, 
noninjected control; E/A13, E/A ADAM13.
Figure 5. Schematic representation of ADAM10 and -13 constructs. 
Domains between ADAM10 (white) and ADAM13 (black) were 
switched as units (Pro/Met and DC   E) or as individual domains 
(D and C). Chimeras containing metalloprotease domains with the 
catalytically inactive E/A point mutation were made. Mutations 
were also made in the disintegrin loops of both ADAM10 and -13. 
All constructs have been myc tagged. Mutated domains are denoted 
by an X. ADAM constructs that cause severe hyperplasia of the 
cement gland when ectopically expressed are designated by an up 
arrow. Blank boxes in this chart indicate that the construct had no 
significant affect on the cement gland. Set A consists of the wild-type 
and E/A point mutant constructs of ADAM10 and -13. Chimeras are 
grouped into Set B, for pro and met domain swaps, and Set C, for 
disintegrin and cysteine-rich domain swaps. Set D groups the 
disintegrin loop alanine point mutations. 
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EGF-like repeat; denoted by an E in Fig. 5) were also ex-
pressed and processed (Fig. 6, B and C; unpublished data).
The same results were observed when the chimeric constructs
were expressed in COS cells or the 
 
Xenopus
 
 cell line XTC (un-
published data). We next checked for cell surface expression
of the constructs using a cell surface biotinylation protocol.
Although endogenous ADAM13 is normally found on the
surface only in its met form (Alfandari et al., 2001), here we
observed both the pro (black arrows) and met (open arrows)
forms on the surface (Fig. 6 B), likely due to overexpression.
All ADAM chimeras and mutants were found on the surface
in both pro and met forms (Fig. 6, B and C). Some of the met
forms (those of 10PM/13, 13PM/10, 13/10DC, 13/10D,
13/10C, 13DisAla, and 10DisAla) were expressed at relatively
high levels, whereas others (10/13DCE, 10/13DC, 10/13D,
and 10/13C) were expressed at lower levels.
Although relatively low levels of the met form of 10/
13DC were present at the cell surface, this chimera had po-
tent cement gland–inducing activity (Fig. 7, Set C; Fig. 8
D); therefore, the quantity of met form present did not cor-
relate with function over the range of concentrations used
in these studies. In addition, the relative amount of met
form to pro form did not appear to influence activity. Chi-
mera 10/13DC had a high pro to met ratio (Fig. 6 B), but
still remains highly effective in inducing cement gland ex-
pansion. Consequently, an abundance of ADAM pro form
on the cell surface did not inhibit the activity of the cleaved
protease active form.
 
The protease domains of ADAM10 and -13 
are functionally interchangeable for inducing 
cement gland hyperplasia
 
Chimeric ADAMs were injected into embryos and analyzed
for XCG expression at stages 20–24 of development. Em-
Figure 6. All ADAM constructs are proteolytically processed and 
found on the cell surface. (A) In whole embryo lysate Western blots 
with the anti–myc tag antibody, 9E10, both wild type and E/A 
mutants of ADAM10, ADAM13, and the Pro/Met chimeras are all 
found in unprocessed precursor forms with the pro-domain (black 
arrow) and in metalloprotease active forms, with the functionally 
repressive pro-domain removed (open arrows). (B and C) By affinity 
purification of cell surface biotin-labeled proteins and Western 
blotting with 9E10, the pro forms (black arrows) and metalloprotease 
forms (met forms, open arrows) of all ADAM constructs are seen. 
The pro and met forms generally run as expected based on calculated 
molecular weights with the addition of the myc tag.
Figure 7. Summary of ADAM10/13 construct expression in 
embryos. The molecular weights in kD were calculated by MacVector 
software and include the addition of the six myc tags and predicted 
N-linked glycosylations. After in situ hybridization with XCG, embryos 
were scored for mild or severe cement gland perturbations. The 
embryos with mild phenotypes were subdivided into two classes, in 
some cases (shown with a back slash), defined as one to three small 
spots of ectopic XCG expression or three to four small spots 
accompanied by  10% expansion of the area of the main cement 
gland. Severe phenotypes had numerous large islands of ectopic 
cement gland or substantial expansions ( 10%) of the existing cement 
gland. Up arrows indicate the ability of a construct to induce severe 
cement gland hyperplasia (corresponding to arrows in Fig. 5). 
Constructs with high levels of cell surface expression in the met form 
(as compared with ADAM13) have two pluses (  ) and embryos with 
lower levels of met forms are given one plus ( ). N, the number of 
embryos assayed. 
aLow cell surface expression, but robust activity. 
*Previously we reported separate experiments involving the 
coexpression of equal amounts of transcript (0.5 ng each) encoding 
wild-type and E/A ADAM13, which led to a marked reduction (62%) in 
cement gland hyperplasia. We conclude that E/A ADAM13 can 
function as a dominant-negative inhibitor of wild-type ADAM13 in the 
cement gland assay; the details are reported in Alfandari et al. (2001). 
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bryos were scored for mild or severe cement gland expan-
sion. The presence of an active metalloprotease site in
ADAM13 was required for hyperplasia of the cement gland
(Fig. 4, D and E; Cousin et al., 2000). Nevertheless, the
ADAM13 metalloprotease domain itself was not required
per se for expansion of XCG expression; strong hyperplasia
was seen in 47% of embryos injected with a chimera in
which the ADAM10 pro and met domains are followed by
the disintegrin, cysteine-rich, EGF-like repeat, transmem-
brane, and cytoplasmic tail domains of ADAM13 (Fig. 7,
Set B, 10PM/13). In contrast, embryos expressing the recip-
rocal chimera composed of ADAM13 pro and met domains
in an ADAM10 background (13PM/10) did not have ex-
panded cement glands (Fig. 7, Set B). As with wild-type
ADAM13, cement gland expansion activity was abolished in
the 10PM/13 chimera when an E to A point mutation was
introduced into the active site of ADAM10 (Fig. 7, E/A
10PM/13). These observations indicate that a functional
protease domain is needed for cement gland induction, but
that specificity for function does not reside within the
ADAM13 protease domain (Fig. 7, Set B). These findings
indicate that a downstream domain of ADAM13 is neces-
sary for specifying the cement gland hyperplasia phenotype.
 
The disintegrin and cysteine-rich domains of ADAM13 
are critical for function
 
In an earlier study we demonstrated that coexpression of
E/A ADAM13 with ADAM13 results in a marked reduction
in cement gland hyperplasia compared with ADAM13 ex-
pression alone (Alfandari et al., 2001). Thus, we conclude
that E/A ADAM13 acts as a dominant-negative inhibitor of
ADAM13 protease activity. Our hypothesis is that it does so
by competing with wild-type ADAM13 for access to sub-
strate. This finding further implicates ADAM13 domains
downstream of the metalloprotease in regulating protease ac-
tivity and/or substrate selectivity. Therefore, we sought to
determine which domain(s) downstream of the ADAM13
metalloprotease domain is necessary to confer the cement
gland expansion phenotype. We ruled out the cytoplasmic
tail as a possible contributing factor because mutants of
ADAM13 in which the tail is deleted still give the expanded
cement gland phenotype (Cousin et al., 2000). We therefore
focused on the disintegrin, cysteine-rich, and EGF-like re-
peat domains. Replacing the disintegrin and cysteine-rich
(DC) domains of ADAM10 with those of ADAM13, with
and without the EGF-like repeat (E), resulted in 22% (for
10/13DCE) and 41% (for 10/13DC) of embryos displaying
severe hyperplasia of the cement gland (Fig. 7, Set C). The
reciprocal chimera, ADAM13 with the disintegrin and cys-
teine-rich domains of ADAM10 (13/10DC), showed less
activity than wild-type ADAM13 and yielded only 11% of
embryos with cement gland expansion (Fig. 7, Set C). Swap-
ping disintegrin domains alone had no effect on the func-
tion of either ADAM10 or ADAM13 in cement gland ex-
pansion. From this set of data, we conclude that either the
ADAM13 cysteine-rich domain alone or the disintegrin and
cysteine-rich domains together are responsible for specifying
the cement gland phenotype (Fig. 7, Set C).
To distinguish the effects of the disintegrin domain from
those of the cysteine-rich domain, the cysteine-rich domains
 
alone were swapped. A chimera in which the cysteine-rich
domain of ADAM13 was placed in ADAM10 caused severe
hyperplasia of the cement gland in 27% of embryos (Fig. 7,
Set C, 10/13C; Fig. 8 H). Although the ADAM13 cysteine-
rich domain alone in an ADAM10 background (10/13C)
was sufficient to enable the chimera to expand the cement
gland, the activity was more robust (41%) in a chimera con-
taining both the disintegrin and cysteine-rich domains of
ADAM13 (Fig. 7, Set C; Fig. 8, compare H with D).
Mutations designed to ablate disintegrin loop adhesive in-
teractions in ADAM13 by replacing three critical amino ac-
ids with alanines (Bigler et al., 2000; Zhu et al., 2000; Taka-
hashi et al., 2001) while keeping the protease domain intact
(13DisAla) abolished cement gland expansion (Fig. 7, Set
D; Fig. 8 J). Like wild-type ADAM13, the 13DisAla con-
struct exhibited protease activity in an in vitro assay (unpub-
lished data); therefore, mutating the disintegrin loop of
ADAM13 does not destroy its inherent proteolytic capabil-
ity. From this analysis we conclude that the ADAM10 and
-13 disintegrin domains, although required, are functionally
interchangeable in this system, but the cysteine-rich do-
mains are functionally distinct and cannot compensate
Figure 8. Anterior views of representative stage-22 Xenopus 
embryos showing XCG mRNA expression. (A) Embryos injected 
with GFP alone have no alterations in XCG expression. (B) Like 
ADAM13, the 10PM/13 chimeric construct causes a large expansion 
in XCG. The 10/13DCE (C) and 10/13DC (D) chimeras also perturb 
the cement gland. (E) An E/A point mutant in the catalytically active 
site of the 10/13DC chimera ablates its ability to cause hyperplasia 
of the cement gland. (F) Replacing ADAM13’s disintegrin and 
cysteine-rich domains (chimera 13/10DC) did not fully ablate the 
XCG expansion, but it did lessen its severity. Replacing the disintegrin 
domain of ADAM13 with that of ADAM10 (chimera 13/10D) did 
not alter the function (G), whereas replacing only ADAM10’s cysteine-
rich domain with that of ADAM13 (10/13C) was sufficient to give 
that chimera the ability to cause alterations in XCG (H). Swapping 
ADAM13’s cysteine-rich domain caused both a quantitative 
(6% severe phenotype vs. 33% for wild-type ADAM13; Fig. 7) and 
qualitative (I) decrease in activity. (J) Three point mutations in the 
disintegrin loop of ADAM13 diminish its ability to cause the 
enlargement of the cement gland, but do not affect its ability to 
cause its own degradation in vitro (unpublished data). 
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for one another. Therefore, the cysteine-rich domain of
ADAM13 is the major determinant specifying protease-
dependent cement gland expansion.
 
Discussion
 
ADAMs are multidomain type I integral membrane proteins
that are noted for their metalloprotease activities. They can
function as sheddases to release active growth factors or cyto-
kines (Blobel, 2000; Primakoff and Myles, 2000; Kherad-
mand and Werb, 2002), or they can cleave ECM com-
ponents (Millichip et al., 1998; Alfandari et al., 2001;
Schwettmann and Tschesche, 2001). Downstream of their
metalloprotease domains, ADAMs contain three other do-
mains that have been implicated as binding partners for other
molecules in vitro. Many ADAM disintegrin domains sup-
port integrin-mediated cell adhesion (Evans, 2001; Taka-
hashi et al., 2001; Bridges et al., 2002; Eto et al., 2002;
White et al., 2002). The cysteine-rich domain of ADAM12
has been suggested to interact with syndecans and 
 
 
 
1 inte-
grins (Iba et al., 2000). In addition, the cytoplasmic tails
of many ADAMs bind SH3 domain–containing ligands
(Howard et al., 1999; Cousin et al., 2000; Kang et al., 2001).
A major hypothesis has been that downstream domains affect
protease function, for example, by helping to specify sub-
strate recognition by the protease domain. Here we have used
a robust activity of ADAM13, induction of cement gland hy-
perplasia in 
 
Xenopus
 
 embryos, to conduct a structure function
analysis of the role of individual ADAM domains in a biolog-
ical activity occurring in a developing organism.
For the present study we constructed a battery of chi-
meras containing domains of 
 
Xenopus
 
 ADAM13 and
ADAM10. In contrast to ADAM13, ADAM10 does not
induce cement gland hyperplasia. We found that the
ADAM10 metalloprotease domain, however, could replace
that of ADAM13 for this activity, indicating that substrate
specificity does not lie within the ADAM13 metalloprotease
domain. Conversely, a chimera containing the cysteine-rich
domain of ADAM13 in an ADAM10 background was able
to induce cement gland hyperplasia, indicating a key role
for the cysteine-rich domain of ADAM13 in this activity.
Two observations suggest that the disintegrin domain of
ADAM13 also plays a supportive role. First, an ADAM10
chimera containing both the disintegrin and cysteine-rich
domains of ADAM13 is a more potent inducer of cement
gland hyperplasia (41% severe hyperplasia) than a chimera
containing only the cysteine-rich domain (27% severe hy-
perplasia). Second, an ADAM13 mutant with alanine sub-
stitutions in its disintegrin loop does not induce cement
gland hyperplasia. Collectively, our results suggest that both
the disintegrin and cysteine-rich domains of ADAM13 are
required for optimal induction of cement gland tissue. A
previous in vitro chimeric analysis involving mammalian
ADAM17 (TACE) and ADAM10 indicated a role for the
“cysteine-rich domains” of ADAM17 for cleaving interleu-
kin 1 receptor type II. However, because the prior study de-
fined the “cysteine-rich domains” as a composite of the dis-
integrin and cysteine-rich domains of ADAM17, it did not
resolve roles for the individual disintegrin or cysteine-rich
domains (Reddy et al., 2000).
 
Model for intramolecular cooperation between 
cysteine-rich and metalloprotease domains
 
Three lines of evidence strongly suggest that the cysteine-
rich domain of ADAM13 functions intramolecularly with
the protease domain to specify cement gland hyperplasia.
First, a chimera containing the ADAM10 metalloprotease
domain followed by the disintegrin and cysteine-rich (DC)
domains of ADAM13 (Fig. 7, Set C) is capable of inducing
cement gland hyperplasia, whereas the same chimera with
an E/A mutation in the protease domain is not. The same
is true for wild-type and E/A ADAM13. Second, E/A
ADAM13 functions as a dominant-negative to inhibit the
ability of wild-type ADAM13 to produce cement gland ex-
pansion when both are coexpressed in the embryo (Alfandari
et al., 2001). Our third line of support is a result of express-
ing a secreted soluble form of the ADAM13 disintegrin and
cysteine-rich domains (DC). Soluble ADAM13 DC does
not lead to any cement gland hyperplasia when expressed on
its own, nor does it have any apparent dominant-negative ef-
fect on expressed wild-type ADAM13 in the cement gland
assay (unpublished data). We therefore conclude that the ce-
ment gland hyperplasia phenotype is a direct result of in-
tramolecular cooperation between the protease domain and
the cysteine-rich domain of ADAM13 and not a result of ei-
ther domain acting alone, in trans.
 
Model for involvement of the cysteine-rich domain in 
selecting ADAM protease substrates
 
We propose that by using its cysteine-rich domain, the
ADAM13 metalloprotease attains a higher level of specificity
or activity in cleaving a substrate(s) that is involved in cement
gland induction. A simple model to explain our observations
is that the cysteine-rich domain of ADAM13 binds to a site
on the protease substrate, thereby facilitating cleavage. As dis-
cussed below, we consider it most likely that ADAM13 acts
as a sheddase to induce cement gland hyperplasia. Hence
the substrate could be a progrowth factor. Alternatively,
the ADAM13 cysteine-rich (and disintegrin) domain(s)
may bind to other receptors that, in turn, help select the
ADAM13 substrate. Such alternate receptors could include
integrins (Zhang et al., 1998; Eto et al., 2002; Bridges et al.,
2002), syndecans (Iba et al., 2000), or ECM components
(Gaultier et al., 2002). However, if the disintegrin domain of
ADAM13 interacts with an integrin to induce cement gland
hyperplasia (or other proteolytic functions), it is likely that
the disintegrin domain–integrin interaction is not highly spe-
cific. In contrast, the cysteine-rich domain of ADAM13 is es-
sential for conferring the ability of the ADAM13 metallopro-
tease domain to induce cement gland tissue. We therefore
propose that the cysteine-rich domain is the key domain of
ADAM13 involved in acting on a substrate, the cleavage of
which initiates cement gland hyperplasia.
The model proposed above suggests that ADAM13 acts as
a sheddase to induce cement gland hyperplasia. Related
models can be invoked for processes involving ADAM-
mediated cleavage of ECM substrates. ADAM13 can cleave
fibronectin and can remodel a fibronectin matrix, activities
that are likely involved in promoting cranial neural crest cell
migration (Alfandari et al., 2001). There may be binding 
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site(s) for the disintegrin and cysteine-rich domains of
ADAM13 on fibronectin or on alternate receptors (e.g., in-
tegrins and syndecans) that help select or position fibronec-
tin for cleavage. Recent data support the former possibility
(although not excluding the latter). A construct containing
the disintegrin and cysteine-rich domains of ADAM13 sup-
ports integrin-mediated cell adhesion and binds to the
HepII domain of fibronectin in vitro (Gaultier et al., 2002).
An alternative, but not mutually exclusive, model for the
role of the cysteine-rich domain of ADAM13 in regulating its
protease activity invokes interactions with an endogenous
inhibitor, such as a tissue inhibitor of metalloproteases
(TIMP). TIMPs can bind to both the protease and/or he-
mopexin domains of MMPs to regulate their activity (Mur-
phy et al., 1992; Baragi et al., 1994). A similar regulatory in-
teraction may occur between some ADAMs and TIMPs
(Amour et al., 2000; Lee et al., 2002). The regulation of
ADAM10/13 chimera protease activity by the disintegrin
and cysteine-rich domains may be a function of specific
TIMP binding to those adhesive domains. If, for example,
ADAM13 is less sensitive than ADAM10 to the inhibitory
effects of TIMPs, replacing ADAM10’s putative TIMP bind-
ing site (the cysteine-rich domain) with that of ADAM13
would create a chimera with greater proteolytic activity.
 
Model for ADAM-mediated cement gland induction
 
Our findings demonstrate that ectopic expression of
ADAM13 leads to cement gland hyperplasia and this activ-
ity depends critically on the cysteine-rich domain. How
might this occur? The ectoderm of the 
 
X
 
.
 
 laevi
 
s embryo is
patterned into nonneuronal versus neuronal tissue by a gra-
dient of BMP4 (Dale and Wardle, 1999). The gradient is
further refined by expression of soluble inhibitors of BMPs
and by expression of other growth factors and morphogens
(Dale and Jones, 1999). Domains of high BMP4 expression
become specified as nonneuronal ectoderm. Mid-ranges of
BMP4 give rise to a field of cells that will become cement
gland. The cement gland field arises at the dorsal–ventral
border and marks the anteriormost part of the embryo. En-
dogenous pro-cement gland signals are present in the dorsal
mesoderm (Gammill and Sive, 2000) where ADAM13 mes-
sage is found. Therefore, it is possible that ADAM13 is
an endogenous effector of cement gland. Alternatively,
ADAM13 may be mimicking another ADAM metallopro-
tease that is an endogenous effector of cement gland tissue.
If ADAM13 does play a role in the development of the ce-
ment gland, then it must do so early, potentially by affecting
the BMP4 gradient itself or a cell’s ability to perceive the
gradient. We reached this conclusion because expression of
ADAM13 does not alter the mRNA expression patterns of
the known cement gland inducers xrx and otx2 (unpub-
lished data). Otx2 can directly turn on the cement gland
marker XCG, and overexpression of otx2 leads to ectopic ce-
ment gland tissue ventrally in areas competent to become ce-
ment gland, as specified by BMP4 (Gammill and Sive,
1997). In contrast, the cement glands observed in embryos
overexpressing ADAM13 are expanded dorsally. Therefore,
when misexpressed anteriorly, ADAM13 can expand the
field of cells that are capable of responding to the endoge-
nous otx2 signaling cascade without altering otx2 directly.
 
Summary
 
In conclusion, this paper reveals an essential role for the cys-
teine-rich domain of an ADAM in regulating protease activ-
ity in vivo. Since their discovery, ADAMs have been identi-
fied in a wide variety of cell types and tissues. Their ability to
process growth factors and cell surface receptors and to re-
model the ECM is required for normal embryonic develop-
ment, and when ADAM behavior goes awry in adult tissue,
disease states may occur. By elucidating the mechanism by
which the disintegrin and cysteine-rich domains help an
ADAM identify and cleave a target substrate, we will begin
to understand how ADAMs and other cell surface proteases
function in development and disease.
 
Materials and methods
 
Embryo culture
 
X
 
.
 
 laevis
 
 eggs were fertilized and the resultant embryos were dejellied in
2% cysteine and cultured as previously described (Newport and Kirschner,
1982). Staging of embryos was according to Nieuwkoop and Faber (1994).
 
Cloning of 
 
X
 
.
 
 laevis
 
 ADAM10
 
Degenerative RT-PCR was performed on stage-34 whole embryo cDNA
using nested primer pairs based on regions of high similarity in the se-
quences of 
 
Drosophila
 
 kuz (GenBank/EMBL/DDBJ accession no. U60591)
and 
 
Bos taurus
 
 MADM (accession no. Z21961). RT-PCR was performed
using two rounds of amplification with primers kuz-s1, 5
 
 
 
-tg/a/t/ctac/tata/c/
tcaa/gacg/a/t/cga-3
 
 
 
, and kuz-as2, 5
 
 
 
-aca/gtca/gcaa/gtag/a/t/ccg/a/t/cc/tg/ta/
gaa-3
 
 
 
, for round one and primers kuz-s2, 5
 
 
 
-tgc/tc/ttg/a/t/cgcg/a/t/ctatgtg/
a/t/cttc/tac-3
 
 
 
, plus kuz-as2 for round two. The 1-kbp product was cloned
into the pCR2.1 TA cloning kit vector (Invitrogen) and used as a probe to
screen an 
 
X
 
.
 
 laevis
 
 st.45 cDNA library. The resulting partial cDNA clone
from that screen was used to probe a 
 
Xenopus
 
 st.17 cDNA library in 
 
 
 
gt10
(Kintner and Melton, 1987), from which a clone containing the entire cod-
ing region of X-ADAM10 was isolated.
 
Production of chimeric constructs and mutants
 
Chimeric constructs of ADAM10 and ADAM13 were initiated by PCR am-
plification of individual domains with the addition of unique restriction
sites engineered within the primers. Pfu DNA polymerase (Strategene) or
Vent DNA polymerase (New England Biolabs, Inc.) was used in order to
ensure high fidelity of amplification. The PCR products were then purified
and incubated with taq DNA polymerase (Promega) before being cloned
into the pCRII-TOPO vector (TOPO TA cloning kit; Invitrogen). The sub-
cloned domain(s) was then excised and ligated back into pCS2
 
 
 
 in the de-
sired order to produce each chimera listed in Fig. 4. Domains were broken
down as in Alfandari et al. (1997), with the disintegrin, cysteine-rich, and
EGF-like domains starting on a cysteine. Alanine mutations were made in
the disintegrin loop of ADAM10 (aa 529, S to A, and aa 530, D to A) and
ADAM13 (aa 474, G to A; aa 475, S to A; and aa 477, D to A) using the
QuikChange site-directed mutagenesis kit (Stratagene) and the follow-
ing primers: ADAM10 forward primer, 5
 
 
 
-tgtcgggaggaagctgcctgtgccaa-
gatgggaa-3
 
 
 
; ADAM10 reverse primer, 5
 
 
 
-ttcccatcttggcacaggcagcttcctc-
ccgaca-3
 
 
 
; ADAM13 forward primer, 5
 
 
 
-tgccgggaaatggctgcagcctgtgccct-
tccggaattct-3
 
 
 
; and ADAM13 reverse primer, 5
 
 
 
-agaattccggaagggcacaggct-
gcagccatttcccggca-3
 
 
 
. PCR conditions were as recommended by the man-
ufacturer, with Pfu DNA polymerase and 10 ng DNA template. All chime-
ras were confirmed by sequencing.
 
Microinjection
 
All constructs were cloned into the pCS2-myc expression vector, linear-
ized with Not I, and transcribed into capped RNA using SP6 RNA poly-
merase (Promega). The transcripts were then run through a ProbeQuant
G-50 spin column (Amersham Biosciences) before being extracted with
phenol/chloroform and precipitated with 2.5 volumes of EtOH and 0.1
volume of 3 M NaAc. The RNAs were then resuspended in water to a final
concentration of 0.1 mg/ml. 1 ng of RNA was injected into the animal pole
region of one blastomere at the two-cell stage. GFP transcripts were coin-
jected with the chimeras, and then the embryos were sorted for left or right
expressers under an epifluorescence dissecting scope before fixation for in
situ hybridization or extraction for Western blots to confirm expression of
the chimeras by probing for the myc epitope. 
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RNA spot blots
 
Total RNA from 10 embryos at various stages was extracted as in Chom-
czynski and Sacchi (1987) with the addition of a LiCl precipitation. Half an
embryo was then spotted onto a nylon membrane using the Schleicher &
Schuell spot blot system according to the manufacturer’s instructions. 
 
XCG
 
(provided by H. Sive, Wellcome Trust, Cambridge, UK) [
 
32
 
P]UTP-labeled
RNA probes were transcribed using the Strip-EZ RNA probe synthesis and
removal kit (Ambion). High stringency conditions were used for both pre-
hybridization and hybridization. Prehybridization occurred in 50% form-
amide, 6  SSPE, 5  Denhardt’s solution, 0.5% SDS, and 100 mg/ml
sheared salmon sperm DNA for 1–2 h at 68 C. Hybridization with probe
was performed in 50% formamide, 6  SSPE, 0.5% SDS, and 100  g/ml
sheared salmon sperm DNA for 24 h at 68 C. Blots were then washed in
1  SSPE/0.5% SDS two times at room temperature and in 0.1  SSPE/0.1%
SDS two to three times at 68 C. The spot blots were exposed to a phosphor
screen for 24–72 h and then quantified using ImageQuant software (IQ
Mac v1.2). The intensity of the RNA spots was analyzed for pixel density,
with darker spots having more RNA and therefore higher density of pixels.
Each sample was within the linear range of detection using storage phos-
phor technology (Johnston et al., 1990).
Whole mount in situ hybridization
Whole mount in situ hybridization on X. laevis embryos was performed as
described by Harland (1991) with a few modifications (Cousin et al.,
2000). Digital image acquisition of the embryos was undertaken in 1 
PBS   0.1% Tween-20 under a dissecting scope, using a Kodak DCS420c
digital camera controlled with an Adobe Photoshop
® plug-in (Kodak).
Whole mount in situ hybridizations with the cement gland–specific probe
XCG were done on all embryos injected with ADAM constructs to ensure
that expansions of the cement gland were scored accurately.
Protein extraction and analysis
After injecting capped RNA transcripts into the embryo and allowing the
embryos to neurulate, groups of 10 embryos were frozen on dry ice and
then solubilized with 200 ml cold embryo solubilization buffer or ESB (100
mM NaCl, 50 mM Tris-HCl, pH 7.5, 1.0% Trition X-100, 2 mM PMSF, 5
mM EDTA). The cellular debris was pelleted by centrifugation at 14,000
rpm for 10 min at 4 C. Extraction with 300 ml of freon removed lipids from
the supernatant, to which an equal volume of 2  laemmli with  -mercap-
toethanol was added before boiling for 5 min and running on a 7% SDS-
PAGE. Proteins were transferred to nitrocellulose membranes (Scleicher &
Schuell) before Western blotting with the anti–myc tag antibody 9E10
(Santa Cruz Biotechnology, Inc.). To analyze cell surface expression, stage
15–16 injected embryos were biotinylated with EZ-Link sulfo-NHS-biotin
(Pierce Chemical Co.) as previously described (Alfandari et al., 1995). To
ensure that only cell surface proteins were biotinylated, control duplicate
immunoprecipitation/Western blots were performed with an antibody to
the cytoplasmic protein tubulin.
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